Stock info Amgen | Filter  Basic-Info

Stock: Amgen (US Tech), ISIN: US0311621009

Last Price 321.91 Max Price 335.97
Min Price 264.06 1 Year return 22.57
Sector Health Care Subsector Biotechnology
Annual report 2020

Amgen is a leading human therapeutics company in the biotechnology industry.
Amgen pioneered the development of novel products based on advances in recombinant DNA and molecular biology and launched the biotechnology industry’s first blockbuster medicines. Today, as a Fortune 500 company serving millions of patients, Amgen continues to be an entrepreneurial, science-driven enterprise dedicated to helping people fight serious illness. Amgen’s stocks are traded in New York and the company is a component of the NASDAQ 100-index (ISIN: US0311621009/ Symbol: AMGN).

Loading...

Contact info:Street: One Amgen Center DriveZip Code: 913201799City: Thousand OaksCountry: USAPhone: 8054471000Email: investor.relations@amgen.comWebsite: www.amgen.comCEO: Robert A. BradwayCFO: Michael A. Kelly

Sector Review Amgen

Loading...
Year Turnover Total sector Market share
2019 23,362 141,925 16.46 %
2020 25,424 170,231 14.93 %
2021 25,979 252,886 10.27 %
2022 26,323 238,500 11.04 %
2023 0 0 0.00 %

Advice Amgen

Date Label Bank Label Stock Label Advice Label Price Label Diff Label
May 17, 2021 Oppenheimer & Co Amgen Buy 270.00 8.74 %
March 06, 2021 JP Morgan Amgen Hold 222.00 -11.00 %
November 01, 2020 Citigroup Amgen Buy 265.00 7.02 %
November 01, 2020 UBS Amgen Hold 229.00 -7.60 %
July 31, 2020 BMO Capital Markets Amgen Buy 308.00 20.00 %
July 31, 2020 Oppenheimer & Co Amgen Buy 270.00 10.20 %
July 31, 2020 JP Morgan Amgen Hold 232.00 -4.51 %
July 31, 2020 Wells Fargo Amgen Hold 247.00 0.24 %
July 31, 2020 Cowen and Company Amgen Buy 297.00 17.03 %
July 31, 2020 Jefferies & Co. Amgen Hold 300.00 17.86 %
July 31, 2020 RBC Capital Markets Amgen Hold 223.00 -10.50 %
July 20, 2020 Oppenheimer & Co Amgen Buy 265.00 7.47 %
April 27, 2020 Oppenheimer & Co Amgen Buy 250.00 -2.02 %
March 27, 2020 Oppenheimer & Co Amgen Buy 240.00 -2.60 %
March 09, 2020 Oppenheimer & Co Amgen Buy 250.00 8.91 %
February 05, 2020 Independent Research Amgen Hold 244.00 -0.99 %
January 24, 2020 Credit Suisse Amgen Hold 252.00 2.22 %
January 24, 2020 Citigroup Amgen Buy 275.00 8.35 %
December 17, 2019 Credit Suisse Amgen Hold 250.00 8.22 %
December 02, 2019 Oppenheimer & Co Amgen Buy 250.00 10.08 %
November 01, 2019 Credit Suisse Amgen Hold 225.00 3.19 %
November 01, 2019 Citigroup Amgen Buy 245.00 11.09 %
November 01, 2019 Cowen and Company Amgen Buy 253.00 13.91 %
August 22, 2019 RBC Capital Markets Amgen Hold 192.00 -24.10 %
August 01, 2019 RBC Capital Markets Amgen Hold 189.00 -29.11 %
August 01, 2019 BMO Capital Markets Amgen Buy 230.00 -6.09 %
August 01, 2019 Citigroup Amgen Buy 215.00 -13.49 %
August 01, 2019 JP Morgan Amgen Hold 191.00 -27.75 %
July 31, 2019 Cowen and Company Amgen Buy 231.00 -7.35 %
July 23, 2019 Credit Suisse Amgen Sell 202.00 -27.87 %
May 24, 2019 Citigroup Amgen Buy
May 21, 2019 RBC Capital Markets Amgen Hold 192.00 -21.45 %
May 17, 2019 Oppenheimer & Co Amgen Buy 210.00 -13.32 %
May 02, 2019 Morgan Stanley Amgen Buy 211.00 -16.78 %
May 02, 2019 Robert W. Baird Amgen Buy 173.00 -42.43 %
May 01, 2019 Oppenheimer & Co Amgen Buy 220.00 -7.13 %
May 01, 2019 Cowen and Company Amgen Buy 229.00 -2.92 %
April 17, 2019 BMO Capital Markets Amgen Buy 229.00 3.14 %
April 07, 2019 KBC Securities Amgen Hold 198.00 -24.45 %
February 26, 2019 Cowen and Company Amgen Buy 234.00 6.89 %



News Amgen

Analysts: this year best year ever for Amgen

Tomorrow the American Amgen will report its past quarters results. For this year Amgen 's (located in ) revenue will be around 26.76 billion USD. This is according to the average of the analysts' estimates. The expected revenue would be the highest in her history....

Analysts foresee more revenue Amgen

Next Monday the American Amgen will report its past quarters results. Over the current book year the total revenu from the company based in Thousand Oaks will be 26.18 billion USD (consensus estimates). This is slightly more than 2021's revenue of 25.98 billion...

Analysts expect over 2021 rising revenue Amgen

Amgen will announce it's last quarter's results tomorrow. Over the current book year the total revenue from the company in Thousand Oaks will be 26.05 billion USD (consensus estimates). This is slightly more than 2021's revenue of 25.42 billion USD. Historical...

Amgen completes $1.9B acquisition of Five Prime Therapeutics

Amgen (NASDAQ:AMGN) announces that it has completed its previously announced tender offer to purchase all outstanding shares of Five Prime Therapeutics (NASDAQ:FPRX) in a deal valued at ~$1.9B. "Five Prime fits squarely within Amgen 's leading oncology...

Amgen to acquire Five Prime Therapeutics for $1.9B

Amgen (NASDAQ:AMGN) and Five Prime Therapeutics (NASDAQ:FPRX) ink merger agreement under which, AMGN will acquire Five Prime for $38.00/share in cash, representing an equity value of ~$1.9B. This acquisition adds Five Prime's innovative pipeline to Amgen 's...

Annual reports Amgen

2017 2018 2019 2020 2021

Profile Amgen

Amgen

(US0311621009)/ AMGN

The company's head quarter is located in Thousand Oaks. The company mostly operates in the biotech sector. Robert A. Bradway is operating by ' CEO. Michael A. Kelly runs the company as a CFO. The global biotech companies gained around 59 percent over the last 10 years. Measured since 2011 the sector is 70 percent higher and over the past 12 months (December 2015-2016) there is a minus of 59 percent.

The past year yielded positive returns for Amgen investors

The stock lost over the past 12 months at around 7 percent. Over the period from December 2011 till December 2016 the stock rose on average 132 percent. Amgen's revenues between 2011 and 2015 were very volatile through the time and moved between 17,27 billion dollars and 21,66 billion dollars. Amgen's net incomes between 2011 and 2015 were very volatile and moved between 3,68 billion dollars and 6,94 billion dollars.

Over the past 5 years the American company paid out dividends. Over the past 5 years Amgen's dividend yield was at around 9,48 percent per year.

Amgen had about 17,9 thousand employees at the end of 2015.

Amgen' balance mostly financed with equity

At the end of 2015 the American company had a balance sheet of around 71,58 billion dollars. Of the total balance sheet 43,49 billion dollars (60,76 percent) was financed by debt. Last year the biotech company's price/earnings-ratio (PE) was around 17. So the investors valued the stock at 17 times 2015' earnings per share. Based on it's price/earnings-ratio and dividend yield the American stock can be seen as a value stock.

At the end of 2015 the American company's market capitalization equaled around 119,11 billion dollars. At the end of 2015 the American company had around 754 million stocks listed.

At this page you find all Amgen's financial reports. More information about Amgen can be found it's website. .


Results Amgen

Results
2015
2016
2017
2018
2019
2020
Revenue
21,662
22,991
22,849
23,747
23,362
25,424
Costs
14,723
15,269
20,870
15,353
15,520
18,160
Profit
6,939
7,722
1,979
8,394
7,842
7,264
Margin of profit
32.03
33.59
8.66
35.35
33.57
28.57
ROI
24.71
25.85
7.84
67.15
81.07
77.20

Balance Amgen

Balance
2015
2016
2017
2018
2019
2020
Equity
28,083
29,875
25,241
12,500
9,673
9,409
Debt
43,366
47,751
54,713
53,916
50,034
53,539
Total assets
71,449
77,626
79,954
66,416
59,707
62,948
Solvency
39.30
38.49
31.57
18.82
16.20
14.95
Cash
31,382
38,085
41,678
29,304
8,911
10,647
Cashflow
9,731
10,354
11,177
11,296
9,150
10,497
Employees
0
0
0
0
0
Revenue per employee
0.0
0.0
0.0
0.0
0.0
Cashflow / Debt
0.22
0.22
0.20
0.21
0.18
0.20

Details Amgen

Details
2016
2017
2018
2019
2020
Price
162.33
146.21
173.90
194.67
241.07
Eps
10.24
2.69
12.62
12.88
12.31
Price/earnings-ratio
15.85
54.35
13.78
15.11
26.15
Dividend
4.00
4.60
5.28
5.80
6.40
Dividend %
2.46 %
3.15 %
3.04 %
2.98 %
1.99 %
Payout %
0.39
1.71
0.42
0.45
0.52
Book value
40.47
34.95
19.85
16.36
16.27
Market to book
0.25
0.24
0.11
0.08
0.05
Cashflow per stock
14.03
15.48
17.94
15.47
18.15
Stocks
738
722
630
591
578
Market Cap
119.832.01
105.592.86
109.487.44
115.127.84
186.160.55

Dividend Amgen


Price info Amgen

Date
Price
08 Nov 2024
321.91
05 Nov 2024
316.91
31 Oct 2024
315.54
29 Oct 2024
317.17
23 Oct 2024
319.66
19 Oct 2024
321.66
16 Oct 2024
325.09
14 Oct 2024
328.35
05 Oct 2024
319.66
02 Oct 2024
320.32
27 Sep 2024
319.10
20 Sep 2024
335.95
17 Sep 2024
335.26
13 Sep 2024
330.06
28 Aug 2024
326.93
26 Aug 2024
328.80
23 Aug 2024
324.53
11 Aug 2024
322.49
07 Aug 2024
328.95
05 Aug 2024
333.99
01 Aug 2024
332.47
30 Jul 2024
332.51
26 Jul 2024
334.30
23 Jul 2024
335.97
16 Jul 2024
330.15
10 Jul 2024
315.91
09 Jul 2024
311.46
04 Jul 2024
309.38
02 Jul 2024
319.31
26 Jun 2024
319.31